Supplementary Table S2 summarizes the MACEs in the cohort, stratified according to the genetic diagnosis of FH. No significant difference in the incidence of MACEs was found between the FH pathogenic variant carriers (n = 41) and non-carriers (n = 244). In addition, 75 patients (26.3%) were found to have revascularization (PCI or CABG) on follow-up (Table 3, left panel). As expected, the FH variant carriers had significantly more revascularization on follow-up than the non-carriers (51.2% vs. 22.1%, p < 0.001), especially those who received CABG (19.5% vs. 2.0%, p < 0.001). This evidence concerns the gene FH and familial hyperaldosteronism.